<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Clin. Infect. Dis</journal-id><journal-id journal-id-type="publisher-id">cid</journal-id><journal-id journal-id-type="hwp">cid</journal-id><journal-title-group><journal-title>Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America</journal-title></journal-title-group><issn pub-type="ppub">1058-4838</issn><issn pub-type="epub">1537-6591</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25520332</article-id><article-id pub-id-type="pmc">4357288</article-id><article-id pub-id-type="doi">10.1093/cid/ciu1128</article-id><article-id pub-id-type="publisher-id">ciu1128</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles and Commentaries</subject></subj-group></article-categories><title-group><article-title>Randomized Trial of Micafungin for the Prevention of Invasive Fungal Infection in High-Risk Liver Transplant Recipients</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Saliba</surname><given-names>Faouzi</given-names></name><xref ref-type="aff" rid="af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Pascher</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cointault</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Laterre</surname><given-names>Pierre-Fran&#x000e7;ois</given-names></name><xref ref-type="aff" rid="af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Cervera</surname><given-names>Carlos</given-names></name><xref ref-type="aff" rid="af5">5</xref></contrib><contrib contrib-type="author"><name><surname>De Waele</surname><given-names>Jan J.</given-names></name><xref ref-type="aff" rid="af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Cillo</surname><given-names>Umberto</given-names></name><xref ref-type="aff" rid="af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>R&#x000f3;bert M.</given-names></name><xref ref-type="aff" rid="af8">8</xref></contrib><contrib contrib-type="author"><name><surname>Lugano</surname><given-names>Manuela</given-names></name><xref ref-type="aff" rid="af9">9</xref></contrib><contrib contrib-type="author"><name><surname>G&#x000f6;ran-Ericzon</surname><given-names>Bo</given-names></name><xref ref-type="aff" rid="af10">10</xref></contrib><contrib contrib-type="author"><name><surname>Phillips</surname><given-names>Stephen</given-names></name><xref ref-type="aff" rid="af11">11</xref></contrib><contrib contrib-type="author"><name><surname>Tweddle</surname><given-names>Lorraine</given-names></name><xref ref-type="aff" rid="af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Karas</surname><given-names>Andreas</given-names></name><xref ref-type="aff" rid="af12">12</xref></contrib><contrib contrib-type="author"><name><surname>Brown</surname><given-names>Malcolm</given-names></name><xref ref-type="aff" rid="af13">13</xref></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Lutz</given-names></name><xref ref-type="aff" rid="af14">14</xref></contrib><on-behalf-of>for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators</on-behalf-of><xref ref-type="author-notes" rid="AN1">a</xref><aff id="af1"><label>1</label><institution>H&#x000f4;pital Paul Brousse</institution>, <addr-line>Villejuif</addr-line>, <country>France</country></aff><aff id="af2"><label>2</label><institution>Charite Universit&#x000e4;tsmedizin</institution>, <addr-line>Berlin</addr-line>, <country>Germany</country></aff><aff id="af3"><label>3</label><institution>H&#x000f4;pital de Rangueil</institution>, <addr-line>Toulouse</addr-line>, <country>France</country></aff><aff id="af4"><label>4</label><institution>St Luc University Hospital, Universit&#x000e9; catholique de Louvain</institution>, <addr-line>Brussels</addr-line>, <country>Belgium</country></aff><aff id="af5"><label>5</label><institution>Hospital Clinic i Provincial</institution>, <addr-line>Barcelona</addr-line>, <country>Spain</country></aff><aff id="af6"><label>6</label><institution>Ghent University Hospital</institution>, <country>Belgium</country></aff><aff id="af7"><label>7</label><institution>Azienda Ospedaliera di Padova</institution>, <country>Italy</country></aff><aff id="af8"><label>8</label><institution>Semmelweis University</institution>, <addr-line>Budapest</addr-line>, <country>Hungary</country></aff><aff id="af9"><label>9</label><institution>Azienda Ospedaliero Universitaria Misericordia</institution>, <addr-line>Udine</addr-line>, <country>Italy</country></aff><aff id="af10"><label>10</label><institution>Karolinska University Hospital</institution>, <addr-line>Huddinge</addr-line>, <country>Sweden</country></aff><aff id="af11"><label>11</label><institution>Astellas Pharma Europe</institution>, <addr-line>Leiden</addr-line>, <country>The Netherlands</country></aff><aff id="af12"><label>12</label><institution>Astellas Pharma Europe Medical Affairs</institution>, <addr-line>Chertsey</addr-line>, <country>United Kingdom</country></aff><aff id="af13"><label>13</label><institution>Astellas Pharma Global Medical Affairs</institution>, <addr-line>Northbrook, Illinois</addr-line></aff><aff id="af14"><label>14</label><institution>University Medical Center Hamburg-Eppendorf</institution>, <country>Germany</country></aff></contrib-group><contrib-group><contrib contrib-type="author"><collab>for the TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) Investigators</collab></contrib><contrib contrib-type="author"><name><surname>Pratschke</surname><given-names>Johann</given-names></name></contrib><contrib contrib-type="author"><name><surname>Decruyenaere</surname><given-names>Johan</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Waele</surname><given-names>Jan J.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Laterre</surname><given-names>Pierre-Fran&#x000e7;ois</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moreno</surname><given-names>Christophe</given-names></name></contrib><contrib contrib-type="author"><name><surname>Michielsen</surname><given-names>Peter</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cointault</surname><given-names>Olivier</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fischer</surname><given-names>Lutz</given-names></name></contrib><contrib contrib-type="author"><name><surname>Neuhaus</surname><given-names>Peter</given-names></name></contrib><contrib contrib-type="author"><name><surname>Pascher</surname><given-names>Andreas</given-names></name></contrib><contrib contrib-type="author"><name><surname>Schemmer</surname><given-names>Peter</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cervera</surname><given-names>Carlos</given-names></name></contrib><contrib contrib-type="author"><name><surname>Varo</surname><given-names>Evaristo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Montejo</surname><given-names>Miguel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bouza</surname><given-names>Emilio</given-names></name></contrib><contrib contrib-type="author"><name><surname>Blanes</surname><given-names>Marino</given-names></name></contrib><contrib contrib-type="author"><name><surname>De La Torre</surname><given-names>Juli&#x000e1;n</given-names></name></contrib><contrib contrib-type="author"><name><surname>Fortun</surname><given-names>Jesus</given-names></name></contrib><contrib contrib-type="author"><name><surname>Saliba</surname><given-names>Faouzi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Rostaing</surname><given-names>Lionel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Paugam-Burtz</surname><given-names>Catherine</given-names></name></contrib><contrib contrib-type="author"><name><surname>Eyraud</surname><given-names>Daniel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Shah</surname><given-names>Tahir</given-names></name></contrib><contrib contrib-type="author"><name><surname>Heaton</surname><given-names>Nigel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>R&#x000f3;bert M.</given-names></name></contrib><contrib contrib-type="author"><name><surname>McCormick</surname><given-names>Aiden</given-names></name></contrib><contrib contrib-type="author"><name><surname>Cillo</surname><given-names>Umberto</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salizzoni</surname><given-names>Mauro</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lugano</surname><given-names>Manuela</given-names></name></contrib><contrib contrib-type="author"><name><surname>De Gasperi</surname><given-names>Andrea</given-names></name></contrib><contrib contrib-type="author"><name><surname>Tom&#x000e9;</surname><given-names>Lu&#x000ed;s</given-names></name></contrib><contrib contrib-type="author"><name><surname>Daniel</surname><given-names>Jorge</given-names></name></contrib><contrib contrib-type="author"><name><surname>Popescu</surname><given-names>Irinel</given-names></name></contrib><contrib contrib-type="author"><name><surname>Moysyuk</surname><given-names>Yan G.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Chzhao</surname><given-names>Alexey V.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Zagaynov</surname><given-names>Vladimir E.</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ericzon</surname><given-names>Bo-G&#x000f6;ran</given-names></name></contrib></contrib-group><author-notes><fn id="AN1" fn-type="con"><label>a</label><p>The TENPIN study investigators are listed in the Appendix.</p></fn><corresp>Correspondence: Faouzi Saliba, MD, PhD, Centre H&#x000e9;pato-Biliaire, H&#x000f4;pital Paul Brousse, 12, av. P. V. Couturier, 94800 Villejuif, France (<email>faouzi.saliba@pbr.aphp.fr</email>).</corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>17</day><month>12</month><year>2014</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>12</month><year>2014</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the
							<pub-date pub-type="epub"/>. --><volume>60</volume><issue>7</issue><fpage>997</fpage><lpage>1006</lpage><history><date date-type="received"><day>14</day><month>7</month><year>2014</year></date><date date-type="accepted"><day>6</day><month>12</month><year>2014</year></date></history><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America.</copyright-statement><copyright-year>2014</copyright-year><license license-type="creative-commons" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact <email>journals.permissions@oup.com</email>.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="ciu1128.pdf"/><abstract abstract-type="precis"><p>In this randomized clinical trial comparing micafungin 100 mg with standard-care antifungal prophylaxis (fluconazole, liposomal amphotericin B, or caspofungin) in high-risk liver transplant patients, micafungin 100 mg was noninferior and had a better kidney safety profile.</p></abstract><abstract><p><bold><italic>Background.</italic></bold>&#x02003;Invasive fungal infection (IFI) following liver transplant is associated with significant morbidity and mortality. Antifungal prophylaxis is rational for liver transplant patients at high IFI risk.</p><p><bold><italic>Methods.</italic></bold>&#x02003;In this open-label, noninferiority study, patients were randomized 1:1 to receive intravenous micafungin 100 mg or center-specific standard care (fluconazole, liposomal amphotericin B, or caspofungin) posttransplant. The primary endpoint was clinical success (absence of a proven/probable IFI and no need for additional antifungals) at end of prophylaxis (EOP). Noninferiority (10% margin) of micafungin vs standard care was assessed in the per protocol and full analysis sets. Safety assessments included adverse events and liver and kidney function tests.</p><p><bold><italic>Results.</italic></bold>&#x02003;The full analysis set comprised 344 patients (172 micafungin; 172 standard care). Mean age was 51.2 years; 48.0% had a Model for End-Stage Liver Disease score &#x02265;20. At EOP (mean treatment duration, 17 days), clinical success was 98.6% for micafungin and 99.3% for standard care (&#x00394; standard care &#x02013; micafungin [95% confidence interval], 0.7% [&#x02212;2.7% to 4.4%]) in the per protocol set and 96.5% and 93.6%, respectively (&#x02212;2.9% [&#x02212;8.0% to 1.9%]), in the full analysis set. Incidences of drug-related adverse events for micafungin and standard care were 11.6% and 16.3%, leading to discontinuation in 6.4% and 11.6% of cases, respectively. At EOP, liver function tests were similar but creatinine clearance was higher in micafungin- vs standard care&#x02013;treated patients.</p><p><bold><italic>Conclusions.</italic></bold>&#x02003;Micafungin was noninferior to standard care as antifungal prophylaxis in liver transplant patients at high risk for IFI. Adverse event profiles and liver function at EOP were similar, although kidney function was better with micafungin.</p><p><bold><italic>Clinical Trials Registration.</italic></bold>&#x02003;NCT01058174.</p></abstract><kwd-group><kwd>antifungal therapy</kwd><kwd>liver transplant</kwd><kwd>micafungin</kwd><kwd>prophylaxis</kwd><kwd>infection</kwd></kwd-group></article-meta></front><body><p>Liver transplant recipients are susceptible to invasive fungal infection (IFI), with infection rates of 8.4%&#x02013;17.7% reported in contemporary epidemiological studies [<xref rid="CIU1128C1" ref-type="bibr">1</xref>&#x02013;<xref rid="CIU1128C6" ref-type="bibr">6</xref>]. Most IFIs in solid organ transplant recipients belong to the genera <italic>Aspergillus</italic> and <italic>Candida</italic> [<xref rid="CIU1128C7" ref-type="bibr">7</xref>, <xref rid="CIU1128C8" ref-type="bibr">8</xref>]. <italic>Candida</italic> species account for the majority (60%&#x02013;91%) of IFI in liver transplant patients [<xref rid="CIU1128C3" ref-type="bibr">3</xref>, <xref rid="CIU1128C5" ref-type="bibr">5</xref>, <xref rid="CIU1128C8" ref-type="bibr">8</xref>, <xref rid="CIU1128C9" ref-type="bibr">9</xref>], with <italic>Candida albicans</italic> and <italic>Candida glabrata</italic> being most commonly observed [<xref rid="CIU1128C8" ref-type="bibr">8</xref>, <xref rid="CIU1128C10" ref-type="bibr">10</xref>, <xref rid="CIU1128C11" ref-type="bibr">11</xref>].</p><p>Risk factors associated with IFI in liver transplant recipients include pre- and postoperative renal failure, retransplantation, substantial intraoperative transfusion of cellular blood products [<xref rid="CIU1128C9" ref-type="bibr">9</xref>], and high Model for End-Stage Liver Disease (MELD) score [<xref rid="CIU1128C2" ref-type="bibr">2</xref>, <xref rid="CIU1128C12" ref-type="bibr">12</xref>, <xref rid="CIU1128C13" ref-type="bibr">13</xref>]. As IFIs are associated with mortality rates of 25%&#x02013;90% [<xref rid="CIU1128C2" ref-type="bibr">2</xref>, <xref rid="CIU1128C4" ref-type="bibr">4</xref>, <xref rid="CIU1128C9" ref-type="bibr">9</xref>, <xref rid="CIU1128C14" ref-type="bibr">14</xref>, <xref rid="CIU1128C15" ref-type="bibr">15</xref>], antifungal prophylaxis is a rational approach for liver transplant patients considered at high risk.</p><p>Fluconazole and liposomal amphotericin B are US guideline&#x02013;recommended options for antifungal prophylaxis in liver transplant recipients with multiple IFI risk factors [<xref rid="CIU1128C15" ref-type="bibr">15</xref>&#x02013;<xref rid="CIU1128C17" ref-type="bibr">17</xref>]. However, some strains of <italic>Candida</italic> have shown resistance to fluconazole [<xref rid="CIU1128C17" ref-type="bibr">17</xref>&#x02013;<xref rid="CIU1128C19" ref-type="bibr">19</xref>], and amphotericin B nephrotoxicity causes concern in renally impaired patients [<xref rid="CIU1128C20" ref-type="bibr">20</xref>, <xref rid="CIU1128C21" ref-type="bibr">21</xref>]. The echinocandins have demonstrated broad efficacy against <italic>Candida</italic> species, have low toxicity and few drug&#x02013;drug interactions, and are established first-line treatments for invasive candidiasis [<xref rid="CIU1128C22" ref-type="bibr">22</xref>&#x02013;<xref rid="CIU1128C24" ref-type="bibr">24</xref>]. Some centers give echinocandins as primary prophylaxis in liver transplant recipients [<xref rid="CIU1128C23" ref-type="bibr">23</xref>], and European recommendations support their use in patients at high IFI risk [<xref rid="CIU1128C25" ref-type="bibr">25</xref>]. The aim of TENPIN (Liver Transplant European Study Into the Prevention of Fungal Infection) was to demonstrate noninferiority of the echinocandin micafungin vs center-specific standard care for IFI prevention in liver transplant recipients deemed at high risk of IFI.</p><sec sec-type="methods" id="s2"><title>METHODS</title><sec id="s2a"><title>Patients and Study Design</title><p>TENPIN was a phase 3b, international, multicenter, randomized, open-label, parallel-group, noninferiority study of antifungal prophylaxis in liver transplant recipients (ClinicalTrials.gov identifier: NCT01058174; ClinicalTrialsRegister.eu EudraCT number 2008-005214-49). Patients aged &#x02265;18 years undergoing orthotopic whole or split liver allograft transplant were eligible for inclusion based on the presence of at least 1 of the IFI risk factors described in <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 1.1. Supplementary Appendix 1.2</ext-link> details the exclusion criteria.</p><p>Eligible patients were randomized 1:1 to receive, posttransplant, either intravenous micafungin 100 mg/day (2.0 mg/kg/day if body weight was &#x0003c;40 kg) or center-specific standard care (a predefined regimen according to local protocol of either intravenous fluconazole 200&#x02013;400 mg/day, intravenous liposomal amphotericin B 1&#x02013;3 mg/kg/day, or intravenous caspofungin 70 mg single loading dose followed by 50 mg once daily). Patients were randomized at admission if they fulfilled the high IFI risk criteria or within 5 days posttransplant following intra- or postoperative events. <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 1.3 and Supplementary Figure 1</ext-link> describe the randomization procedure.</p><p>Prophylaxis lasted 21 days or until hospital discharge (whichever occurred first), or longer in patients with persistent risk factors. End of study (EOS) was 3 months postrandomization, and long-term follow-up was 6 months postrandomization. Patients who developed a proven or probable IFI during prophylaxis were discontinued from the study drug, treated with appropriate antifungal therapy, and required to remain in the study and complete all assessments. A proven or probable IFI, diagnosed by an investigator according to the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group definitions [<xref rid="CIU1128C26" ref-type="bibr">26</xref>], was confirmed by an independent data review board (IDRB).</p><p>The study protocol (ISN/protocol 9463-EC-0001) was approved by the independent Ethics committee or institutional review board at each center and was conducted in accordance with the ethical principles that originate in the Declaration of Helsinki. Patients' written informed consent was obtained prior to screening.</p><p>The manuscript was written in accordance with the CONSORT (Consolidated Standards for Reporting Trials) statement for randomized controlled trials recommendations [<xref rid="CIU1128C27" ref-type="bibr">27</xref>].</p></sec><sec id="s2b"><title>Outcomes</title><sec id="s2b1"><title>Efficacy</title><p>Fungal infection status was evaluated at baseline (methods provided in <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 1.4</ext-link>), during prophylaxis, at end of prophylaxis (EOP), and at EOS by the investigator and blindly assessed by the IDRB. During prophylaxis, fungal infection status was assessed at a minimum of twice weekly, with assessments conducted at least 72 hours apart.</p><p>The primary efficacy endpoint was clinical success (defined as a composite of absence of a proven or probable IFI and no initiation of antifungal treatment at EOP) assessed by the IDRB. Antifungal treatment was defined as either additional antifungal medication or increased study drug dose due to apparent inadequate efficacy.</p><p>Secondary prespecified efficacy endpoints included absence of a proven or probable IFI at EOP and EOS or EOS-month 3 (ie, later than postrandomization day 76) as assessed by the IDRB and investigator; absence of initiation of antifungal therapy at EOP as assessed by the IDRB; time to proven or probable IFI from randomization according to the IDRB; fungal-free survival at EOS; and end of long-term follow-up according to the investigator.</p></sec><sec id="s2b2"><title>Safety</title><p>Treatment-emergent adverse events (AEs) were recorded up to EOS, and serious AEs, including death, until 30 days after EOS. Overall mortality was considered a safety parameter. Routine laboratory assessments of biochemistry, hematology, and urinalysis were performed at baseline and throughout the study. Hepatic and renal function was assessed using standard laboratory biochemical tests.</p></sec></sec><sec id="s2c"><title>Statistical Analysis</title><p>Efficacy data were analyzed for the full analysis set (FAS), that is, all randomized patients who received at least 1 dose of study medication and without proven or possible IFI at baseline (according to the IDRB); and the per protocol set (PPS), that is, all FAS patients who completed the study without major protocol violations. The PPS was used as the primary analysis set and the FAS as the confirmatory analysis set for the primary efficacy endpoint and all secondary endpoints. The safety analysis set (SAF) included all randomized patients who received at least 1 dose of study medication.</p><p>The study sample size was calculated using a noninferiority margin of 10% for the absolute difference in clinical success rates based on clinical judgment by an expert panel. Based on this noninferiority margin, assuming a true success rate of 94% in the standard care group, 135 patients per group were necessary to demonstrate noninferiority of micafungin vs standard care with a power of at least 90% using a 1-sided type I risk error of 2.5%. Assuming that 80% of the randomized subjects were included in the PPS, 169 patients were required to be randomized into each treatment group. Clinically, a noninferiority margin of 10% was also deemed applicable to the FAS.</p><p>For the composite primary efficacy endpoint of clinical success, rates were compared between the standard care and micafungin groups at EOP, and 2-sided 95% confidence intervals (CIs) for the difference in success rates were calculated using the Newcombe&#x02013;Wilson method. If the upper limit of the 95% CI for the difference in success rates was &#x0003c;10%, then the noninferiority of micafungin to standard care was declared. The analysis assumed that the infection rate among the individual treatment regimens was homogeneous. The secondary efficacy endpoints of absence of proven or probable IFI (EOP, EOS, and EOS-month 3) and absence of antifungal therapy (EOP), and fungal-free survival were similarly analyzed, although as the study was powered for the primary endpoint, statistical noninferiority was tested on this endpoint only.</p><p>Time to proven or probable IFI was modeled using Cox regression, with covariates including baseline MELD score (&#x02264;29 or &#x02265;30) and treatment group. Patients with no proven or probable IFI during prophylaxis were censored at the assessment visit. Nonparametric analysis was undertaken, Kaplan&#x02013;Meier curves are provided, and the log-rank test was utilized to compare treatment groups for the endpoints of time to proven or probable IFI and fungal-free survival.</p><p>Baseline characteristics (FAS) and safety variables (SAF) were summarized by descriptive statistics.</p><p>In a post hoc analysis to further explore renal safety, estimates of glomerular filtration rate (GFR) and creatinine clearance (CrCl) were derived for the SAF and also for the SAF patients who did not require renal replacement therapy (RRT) at baseline, using the 4-variable Modification of Diet in Renal Disease formula and Cockcroft&#x02013;Gault formula, respectively. Differences in GFR and CrCl between treatment groups were compared at weekly time points using repeated measures analysis of variance and at EOP by analysis of covariance.</p><p>Data analysis for this paper was generated using SAS/STAT software, version 9.3 (SAS Institute Inc, Cary, North Carolina).</p></sec></sec><sec sec-type="results" id="s3"><title>RESULTS</title><sec id="s3a"><title>Patients</title><p>The study ran from 15 December 2009 to 3 May 2012 at 37 European centers. Figure <xref ref-type="fig" rid="CIU1128F1">1</xref> shows participant flow. Forty-five micafungin-treated patients were excluded from the study, mainly due to AEs (n = 27) or withdrawal of consent (n = 9), and 30 patients treated with standard care were excluded, mainly due to AEs (n = 23). Excluding MELD score, demographic and baseline characteristics were balanced between treatment groups (Table <xref ref-type="table" rid="CIU1128TB1">1</xref>). The most common indications for transplantation were cirrhosis (67.5%) and hepatocellular carcinoma (16.2%). <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.1 and Supplementary Table 1</ext-link> detail the proportion of patients in each high-risk IFI category. The mean duration of exposure was 16.7 (standard deviation [SD], 7.0) days in the micafungin group and 17.1 (SD, 8.0) days in the standard care group.
<table-wrap id="CIU1128TB1" position="float"><label>Table 1.</label><caption><p>Demographic and Baseline Characteristics</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="center" rowspan="1" colspan="1">Micafungin 100 mg (n = 172)</th><th align="center" rowspan="1" colspan="1">Standard Care (n = 172)</th><th align="center" rowspan="1" colspan="1">Total (n = 344)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Male sex, No. (%)</td><td rowspan="1" colspan="1">118 (68.6)</td><td rowspan="1" colspan="1">114 (66.3)</td><td rowspan="1" colspan="1">232 (67.4)</td></tr><tr><td rowspan="1" colspan="1">Mean &#x000b1; SD age, y</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">51.9 &#x000b1; 10.5</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">50.5 &#x000b1; 11.8</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">51.2 &#x000b1; 11.2</td></tr><tr><td rowspan="1" colspan="1">Mean &#x000b1; SD BMI, kg/m<sup>2</sup></td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.8 &#x000b1; 4.3</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.3 &#x000b1; 5.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">25.6 &#x000b1; 4.6</td></tr><tr><td colspan="4" rowspan="1">Ethnicity, No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;White</td><td rowspan="1" colspan="1">165 (95.9)</td><td rowspan="1" colspan="1">159 (92.4)</td><td rowspan="1" colspan="1">324 (94.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Black</td><td rowspan="1" colspan="1">3 (1.7)</td><td rowspan="1" colspan="1">7 (4.1)</td><td rowspan="1" colspan="1">10 (2.9)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Asian</td><td rowspan="1" colspan="1">3 (1.7)</td><td rowspan="1" colspan="1">5 (2.9)</td><td rowspan="1" colspan="1">8 (2.3)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Other</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">1 (0.6)</td><td rowspan="1" colspan="1">2 (0.6)</td></tr><tr><td colspan="4" rowspan="1">Region, No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Western Europe</td><td rowspan="1" colspan="1">71 (41.3)</td><td rowspan="1" colspan="1">72 (41.9)</td><td rowspan="1" colspan="1">143 (41.6)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Eastern Europe</td><td rowspan="1" colspan="1">17 (9.9)</td><td rowspan="1" colspan="1">14 (8.1)</td><td rowspan="1" colspan="1">31 (9.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Southern Europe</td><td rowspan="1" colspan="1">84 (48.8)</td><td rowspan="1" colspan="1">86 (50.0)</td><td rowspan="1" colspan="1">170 (49.4)</td></tr><tr><td rowspan="1" colspan="1">Mean &#x000b1; SD MELD score</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">19.9 &#x000b1; 10.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">21.1 &#x000b1; 10.0</td><td align="char" char="&#x000b1;" rowspan="1" colspan="1">20.5 &#x000b1; 10.0</td></tr><tr><td colspan="4" rowspan="1">MELD score, No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x0003c;20</td><td rowspan="1" colspan="1">98 (57.0)</td><td rowspan="1" colspan="1">81 (47.1)</td><td rowspan="1" colspan="1">179 (52.0)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;20&#x02013;29</td><td rowspan="1" colspan="1">43 (25.0)</td><td rowspan="1" colspan="1">54 (31.4)</td><td rowspan="1" colspan="1">97 (28.2)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;&#x02265;30</td><td rowspan="1" colspan="1">31 (18.0)</td><td rowspan="1" colspan="1">37 (21.5)</td><td rowspan="1" colspan="1">68 (19.8)</td></tr><tr><td colspan="4" rowspan="1">CMV mismatch (recipient/donor), No. (%)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative/negative</td><td rowspan="1" colspan="1">26 (15.2)</td><td rowspan="1" colspan="1">20 (11.8)</td><td rowspan="1" colspan="1">46 (13.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Negative/positive</td><td rowspan="1" colspan="1">27 (15.8)</td><td rowspan="1" colspan="1">23 (13.5)</td><td rowspan="1" colspan="1">50 (14.7)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive/negative</td><td rowspan="1" colspan="1">34 (19.9)</td><td rowspan="1" colspan="1">46 (27.1)</td><td rowspan="1" colspan="1">80 (23.5)</td></tr><tr><td rowspan="1" colspan="1">&#x02003;Positive/positive</td><td rowspan="1" colspan="1">70 (40.9)</td><td rowspan="1" colspan="1">67 (39.4)</td><td rowspan="1" colspan="1">137 (40.2)</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><p>Percentages are based on all patients with available data in the respective treatment regimen. For CMV mismatch, the number of patients with available data is equal to the number of patients with both assessments available.</p></fn><fn id="TN2"><p>Abbreviations: BMI, body mass index; CMV, cytomegalovirus; MELD, Model for End-Stage Liver Disease; SD, standard deviation.</p></fn></table-wrap-foot></table-wrap>
<fig id="CIU1128F1" position="float"><label>Figure 1.</label><caption><p>Disposition of patients. *All randomized patients with at least 1 dose of study drug. <sup>&#x02020;</sup>All randomized patients with at least 1 dose of study drug and without an invasive fungal infection (IFI) at baseline. <sup>&#x02021;</sup>All patients who completed the study without major protocol deviations or violations. <sup>&#x000a7;</sup>Patients from the full analysis set who discontinued; for every patient, only the primary reason for discontinuation was collected.</p></caption><graphic xlink:href="ciu112801"/></fig></p></sec><sec id="s3b"><title>Efficacy</title><sec id="s3b1"><title>Primary Efficacy Endpoint</title><p>The clinical success rate of micafungin 100 mg was noninferior to standard care at EOP as assessed by the IDRB in the primary analysis PPS: 98.6% (138/140) for micafungin and 99.3% (136/137) for standard care (&#x00394; standard care &#x02013; micafungin, 0.7% [95% CI, &#x02212;2.7% to 4.4%]). This was confirmed in the FAS (Table <xref ref-type="table" rid="CIU1128TB2">2</xref>). Of the 67 FAS patients excluded from PPS, 67.1% were excluded because their EOP assessment was &#x0003e;3 days after last treatment administration of study drug.
<table-wrap id="CIU1128TB2" position="float"><label>Table 2.</label><caption><p>Clinical Success Rate for Micafungin and Standard Care at the End of the Prophylaxis Period and as Assessed by the Independent Data Review Board (Per Protocol and Full Analysis Sets)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char=" " span="1"/><col align="char" char=" " span="1"/><col align="char" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Per Protocol Set (Primary Analysis)</th><th align="center" rowspan="1" colspan="1">Micafungin, No. (%) (n = 140)</th><th align="center" rowspan="1" colspan="1">Standard Care, No. (%) (n = 137)</th><th align="center" rowspan="1" colspan="1">Difference, % (95% CI) Standard Care &#x02013; Micafungin</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Clinical success</td><td rowspan="1" colspan="1">138 (98.6)</td><td rowspan="1" colspan="1">136 (99.3)</td><td rowspan="1" colspan="1">0.7 (&#x02212;2.7 to 4.4)</td></tr><tr><td rowspan="1" colspan="1">No clinical success</td><td rowspan="1" colspan="1">2 (1.4)</td><td rowspan="1" colspan="1">1 (0.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Invasive fungal infection<sup>a</sup></td><td rowspan="1" colspan="1">2 (1.4)</td><td rowspan="1" colspan="1">1 (0.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Antifungal treatment<sup>a</sup></td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No assessments available</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1">0</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Full Analysis Set (Confirmatory Analysis)</td><td rowspan="1" colspan="1">Micafungin, (n = 172) No. (%)</td><td rowspan="1" colspan="1">Standard Care, (n = 172) No. (%)</td><td rowspan="1" colspan="1">Difference, % (95% CI) Standard Care &#x02013; Micafungin</td></tr><tr><td rowspan="1" colspan="1">Clinical success</td><td rowspan="1" colspan="1">166 (96.5)</td><td rowspan="1" colspan="1">161 (93.6)</td><td rowspan="1" colspan="1">&#x02212;2.9 (&#x02212;8.0 to 1.9)</td></tr><tr><td rowspan="1" colspan="1">No clinical success</td><td rowspan="1" colspan="1">6 (3.5)</td><td rowspan="1" colspan="1">11 (6.4)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Invasive fungal infection<sup>a</sup></td><td rowspan="1" colspan="1">4 (2.3)</td><td rowspan="1" colspan="1">8 (4.7)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Antifungal treatment<sup>a</sup></td><td rowspan="1" colspan="1">2 (1.2)</td><td rowspan="1" colspan="1">7 (4.1)</td><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">No assessments available</td><td rowspan="1" colspan="1">2 (1.2)</td><td rowspan="1" colspan="1">3 (1.7)</td><td rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="TN3"><p>Abbreviation: CI, confidence interval.</p></fn><fn id="TN4"><p><sup>a</sup> One patient may have proven or probable invasive fungal infection and may have started antifungal treatment.</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="s3b2"><title>Secondary Efficacy Endpoints in the Full Analysis Set</title><p>Micafungin was similar to standard care with regard to absence of proven or probable IFI at EOP and EOS, according to both IDRB and investigator assessments (<ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.2 and Supplementary Table 2</ext-link>). At EOP, there were 4 (2.3%) IDRB-confirmed IFIs in micafungin-treated patients and 8 (4.7%) in standard care&#x02013;treated patients. At EOS, there were 3 new infections in each group. <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.3 and Supplementary Table 3</ext-link> detail the infecting species. With regard to absence of initiation of systemic antifungal treatment, the success rate of micafungin (98.8%) was also similar to standard care (95.9%) at EOP (&#x00394; standard care &#x02013; micafungin, &#x02212;3.0% [95% CI, &#x02212;7.2% to .7%]).</p><p>Cox regression modeling of time to proven or probable IFI gave a hazard ratio of 0.72 (95% CI, .27&#x02013;1.90) indicating no significant difference between the groups. Nonparametric analysis was consistent with this finding (log-rank test <italic>P</italic> = .498; <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.4 and Supplementary Figure 2</ext-link>).</p><p>Investigator-assessed fungal-free survival at EOS was 80.8% (126/156) and 83.2% (139/167) in the micafungin- and standard care&#x02013;treated patients, respectively (&#x00394; 2.5% [95% CI, &#x02212;5.9% to 10.9%]) and at the end of long-term follow-up was 78.1% (121/155) and 80.0% (132/165), respectively (&#x00394; 1.9% [95% CI, &#x02212;7.0% to 10.9%]). Kaplan&#x02013;Meier analyses showed no significant difference in fungal-free survival at long-term follow-up (log-rank <italic>P</italic> = .679) (Figure <xref ref-type="fig" rid="CIU1128F2">2</xref>).
<fig id="CIU1128F2" position="float"><label>Figure 2.</label><caption><p>Fungal-free survival in micafungin and standard care treatment groups during long-term follow-up (full analysis set). Abbreviation: IFI, invasive fungal infection.</p></caption><graphic xlink:href="ciu112802"/></fig></p></sec></sec><sec id="s3c"><title>Safety</title><sec id="s3c1"><title>Hepatic and Renal Functions</title><p>There were no clinically relevant differences in hepatic function tests over time between micafungin- and standard care&#x02013;treated patients (<ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.5 and Supplementary Figure 3</ext-link>).</p><p>Serum creatinine and urea levels were lower in the micafungin group than standard care at most weekly time points and at EOP, suggesting better renal function in these patients. Post hoc analysis showed that mean GFR and mean CrCl were higher for micafungin vs standard care at most time points during prophylaxis, although differences were not statistically significant (<ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.5 and Supplementary Figure 4</ext-link>). However, at EOP when data from all patients at any time were considered, mean GFR was significantly higher in micafungin- vs standard care&#x02013;treated patients (<italic>P</italic> = .049), as was mean CrCl (<italic>P</italic> = .012). For patients not requiring RRT at baseline, significantly higher mean GFR (<italic>P</italic> = .033) and mean CrCl (<italic>P</italic> = .013) were observed for micafungin (n = 133) vs standard care (n = 142) at EOP, although not at weekly time points. Liposomal amphotericin B was associated with the lowest GFR and CrCl in standard care patients (Figure <xref ref-type="fig" rid="CIU1128F3">3</xref><italic>A</italic> and <xref ref-type="fig" rid="CIU1128F3">3</xref><italic>B</italic>).
<fig id="CIU1128F3" position="float"><label>Figure 3.</label><caption><p>Mean glomerular filtration rate (<italic>A</italic>) and mean creatinine clearance (<italic>B</italic>) in patients not requiring renal replacement therapy, according to specific study drug. Abbreviations: EOP, end of prophylaxis; EOS, end of study.</p></caption><graphic xlink:href="ciu112803"/></fig></p></sec><sec id="s3c2"><title>Treatment-Emergent Adverse Events</title><p>There were fewer AEs leading to study drug discontinuation in micafungin- than standard care&#x02013;treated patients (6.4% vs 11.6%, respectively, for treatment-related AEs; <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.6 and Supplementary Table 4</ext-link>). Table <xref ref-type="table" rid="CIU1128TB3">3</xref> shows AEs reported in &#x0003e;10% of patients in either treatment group. Although a higher overall rate of graft rejection was reported for micafungin (19.1%) than standard care (11%), the rates of biopsy-confirmed, treated acute rejection were similar between the 2 groups (9.8% and 8.1%, respectively). Most graft rejections were mild to moderate in severity, and the rate of severe rejections was the same in each group (2.3%). The most common treatment-related AEs are detailed in <ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary Appendix 2.6</ext-link>.
<table-wrap id="CIU1128TB3" position="float"><label>Table 3.</label><caption><p>Treatment-Emergent Adverse Events in &#x0003e;10% of Patients in the Micafungin Treatment or Standard Care Group (Safety Analysis Set)</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="(" span="1"/><col align="char" char="(" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Treatment-Emergent Adverse Events</th><th align="center" rowspan="1" colspan="1">Micafungin (n = 173), No. (%)</th><th align="center" rowspan="1" colspan="1">Standard Care (n = 172), No. (%)</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Abdominal pain</td><td rowspan="1" colspan="1">21 (12.1)</td><td rowspan="1" colspan="1">15 (8.7)</td></tr><tr><td rowspan="1" colspan="1">Diarrhea</td><td rowspan="1" colspan="1">19 (11.0)</td><td rowspan="1" colspan="1">19 (11.0)</td></tr><tr><td rowspan="1" colspan="1">Pleural effusion</td><td rowspan="1" colspan="1">26 (15.0)</td><td rowspan="1" colspan="1">38 (22.1)</td></tr><tr><td rowspan="1" colspan="1">Anemia</td><td rowspan="1" colspan="1">20 (11.6)</td><td rowspan="1" colspan="1">23 (13.4)</td></tr><tr><td rowspan="1" colspan="1">Liver transplant rejection (clinical)</td><td rowspan="1" colspan="1">29 (16.8)</td><td rowspan="1" colspan="1">14 (8.1)</td></tr><tr><td rowspan="1" colspan="1">Pyrexia</td><td rowspan="1" colspan="1">16 (9.2)</td><td rowspan="1" colspan="1">19 (11.0)</td></tr><tr><td rowspan="1" colspan="1">Hypertension</td><td rowspan="1" colspan="1">26 (15.0)</td><td rowspan="1" colspan="1">18 (10.5)</td></tr><tr><td rowspan="1" colspan="1">Cholestasis</td><td rowspan="1" colspan="1">12 (6.9)</td><td rowspan="1" colspan="1">19 (11.0)</td></tr></tbody></table></table-wrap></p></sec><sec id="s3c3"><title>Deaths</title><p>In the micafungin group, 14 patients died during prophylaxis and 15 during long-term follow-up; in the standard care group, 11 died during prophylaxis and 12 during long-term follow-up. Two deaths (1 in each group) were considered to be possibly study drug related by the investigator. Cause of death was mostly septic shock with multiorgan failure and/or worsening of the underlying disease.</p></sec></sec></sec><sec sec-type="discussion" id="s4"><title>DISCUSSION</title><p>TENPIN is the first randomized controlled trial of an echinocandin as prophylaxis in liver transplant patients and the largest antifungal study in this patient population to date. Micafungin demonstrated a clinical success rate that was statistically noninferior to standard care, confirming that micafungin 100 mg is as effective as standard care for antifungal prophylaxis in liver transplant recipients at high risk of IFI. In addition, micafungin had similar efficacy to standard care across all secondary efficacy outcomes assessed. Having an IDRB confirm the investigator's decision based on a standard definition [<xref rid="CIU1128C26" ref-type="bibr">26</xref>] strengthens the study results and was necessary, given that the definition of IFI can vary between centers and physicians.</p><p>IFI rates of up to 17.7% [<xref rid="CIU1128C1" ref-type="bibr">1</xref>&#x02013;<xref rid="CIU1128C6" ref-type="bibr">6</xref>] and 3-month cumulative IFI rates of approximately 4% [<xref rid="CIU1128C10" ref-type="bibr">10</xref>] have been reported in liver transplant recipients without risk factors. The overall low rate of IFI (&#x02264;2%) in our study provides evidence supporting antifungal prophylaxis in high-risk liver transplant recipients. Micafungin is indicated for prophylaxis against <italic>Candida</italic> infection in other high-risk patient groups [<xref rid="CIU1128C28" ref-type="bibr">28</xref>, <xref rid="CIU1128C29" ref-type="bibr">29</xref>]; low rates of breakthrough IFI were observed for micafungin 50 mg (1.6%) and fluconazole (2.4%) in a trial comparing these agents in hematopoietic stem cell transplant recipients [<xref rid="CIU1128C30" ref-type="bibr">30</xref>]. In that study [<xref rid="CIU1128C30" ref-type="bibr">30</xref>], 1 patient on micafungin had a breakthrough <italic>Aspergillus</italic> infection (7 on fluconazole), whereas 2 patients on micafungin in the current study were infected with <italic>Aspergillus</italic> species and 2 on standard care (1 each with fluconazole and liposomal amphotericin B).</p><p>The overall safety profile of micafungin was comparable to that of standard care, with a low incidence of hepatic and renal AEs. The pattern of liver function tests was similar between micafungin and standard care; however, renal function with micafungin may be better than with established standard care regimens, such as liposomal amphotericin B. This is consistent with a prophylaxis study in high-risk liver transplant recipients where micafungin was similarly efficacious to amphotericin B lipid complex, with lower early renal dysfunction and no additional risk of hepatic dysfunction [<xref rid="CIU1128C21" ref-type="bibr">21</xref>]. In our study, more graft rejection episodes were reported in micafungin patients than standard care. However, further investigation found similar rates of biopsy-confirmed treated acute rejection&#x02014;an objective measure of rejection&#x02014;and there was no evidence that micafungin differed from standard care in this regard.</p><p>Alternatives to fluconazole and liposomal amphotericin B, the current guideline-recommended options for antifungal prophylaxis in liver transplant recipients, are needed. <italic>Candida</italic> species such as <italic>C. glabrata</italic> and <italic>C. krusei</italic> are less susceptible, or even resistant in the case of fluconazole, to these agents [<xref rid="CIU1128C17" ref-type="bibr">17</xref>&#x02013;<xref rid="CIU1128C19" ref-type="bibr">19</xref>, <xref rid="CIU1128C31" ref-type="bibr">31</xref>]. Drug&#x02013;drug interactions with fluconazole complicate dosing with the immunosuppressants ciclosporin, tacrolimus, and sirolimus [<xref rid="CIU1128C32" ref-type="bibr">32</xref>]. Fluconazole requires dose adjustment in patients receiving RRT, as the procedure results in a significant clearance of fluconazole, which varies depending on the technique used [<xref rid="CIU1128C33" ref-type="bibr">33</xref>, <xref rid="CIU1128C34" ref-type="bibr">34</xref>]. Although nephrotoxicity risk is reduced with liposomal amphotericin B compared with amphotericin B deoxycholate [<xref rid="CIU1128C15" ref-type="bibr">15</xref>, <xref rid="CIU1128C17" ref-type="bibr">17</xref>], it may still limit its use [<xref rid="CIU1128C20" ref-type="bibr">20</xref>, <xref rid="CIU1128C35" ref-type="bibr">35</xref>], especially in recipients with renal dysfunction.</p><p>Echinocandins may be useful alternatives for simplifying antifungal prophylaxis in liver transplant, exhibiting excellent fungicidal activity against <italic>Candida</italic> species, with low minimum inhibitory concentrations against the majority of isolates [<xref rid="CIU1128C36" ref-type="bibr">36</xref>, <xref rid="CIU1128C37" ref-type="bibr">37</xref>]. Resistance to echinocandins is a relatively rare event [<xref rid="CIU1128C37" ref-type="bibr">37</xref>&#x02013;<xref rid="CIU1128C39" ref-type="bibr">39</xref>]. However, cases of resistance due to therapy-acquired <italic>FKS</italic> mutations have been reported [<xref rid="CIU1128C37" ref-type="bibr">37</xref>, <xref rid="CIU1128C38" ref-type="bibr">38</xref>], and evidence of increasing resistance among strains of <italic>C. glabrata</italic> has emerged [<xref rid="CIU1128C40" ref-type="bibr">40</xref>]. The probability of resistance may increase as echinocandin use escalates, and this needs to be considered when employing these agents as primary prophylaxis with prolonged exposure. As echinocandins do not interact with the P450 cytochrome or P-glycoprotein systems, they have a low potential for drug&#x02013;drug interactions [<xref rid="CIU1128C36" ref-type="bibr">36</xref>, <xref rid="CIU1128C37" ref-type="bibr">37</xref>]. However, caspofungin [<xref rid="CIU1128C41" ref-type="bibr">41</xref>], but not micafungin [<xref rid="CIU1128C42" ref-type="bibr">42</xref>&#x02013;<xref rid="CIU1128C45" ref-type="bibr">45</xref>], does interact with ciclosporin and tacrolimus, and micafungin interacts with sirolimus [<xref rid="CIU1128C28" ref-type="bibr">28</xref>].</p><p>This study's main limitations include those inherently associated with open-label trials, such as potential bias, which can, for example, lead to greater withdrawal of consent in 1 treatment arm. This was observed in this study, as 9 patients on micafungin withdrew consent compared with none on standard care. In addition, standard care therapy was decided as per local guidelines and standard care dosing was not uniform (although it was within a preagreed range and consistent with each center), which may have impacted results. As the choice of standard care was center specific, and therefore could be based on local epidemiology or other clinical considerations relevant to the local patient population, this could be considered as a positive bias in favor of standard care in the TENPIN clinical trial setting. For the post hoc safety analysis on renal function, it was only possible to exclude patients who had RRT at baseline, because information on whether they received RRT during prophylaxis or thereafter was not collected. In addition, it was not possible to adjust for known nephrotoxic concomitant medications.</p><p>In summary, micafungin was demonstrated to be noninferior to standard care for antifungal prophylaxis in liver transplant patients at high risk of IFI, with a similar overall safety profile but associated with better renal function throughout prophylaxis than standard care. Micafungin therefore provides an additional prophylactic option, especially in patients with a high risk of infection by species resistant to current standard care, patients at risk of drug&#x02013;drug interactions, or patients with renal impairment or receiving RRT.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supplementary Data</title><p><ext-link ext-link-type="uri" xlink:href="http://cid.oxfordjournals.org/lookup/suppl/doi:10.1093/cid/ciu1128/-/DC1">Supplementary materials</ext-link> are available at <italic>Clinical Infectious Diseases</italic> online (<uri xlink:type="simple" xlink:href="http://cid.oxfordjournals.org">http://cid.oxfordjournals.org</uri>). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.</p>
<supplementary-material id="PMC_1" content-type="local-data">
<caption>
<title>Supplementary Data</title>
</caption>
<media mimetype="text" mime-subtype="html" xlink:href="supp_60_7_997__index.html"/>
<media xlink:role="associated-file" mimetype="application" mime-subtype="msword"
xlink:href="supp_ciu1128_ciu1128supp.docx"/>
</supplementary-material>
</sec></body><back><ack><title>Notes</title><p><bold><italic>Acknowledgments.</italic></bold>&#x02003;Medical writing assistance was provided by Lisa Thomas, PhD, Connect2CME Ltd, Westerham, United Kingdom.</p><p><bold><italic>Author contributions.</italic></bold>&#x02003;The study sponsor, together with lead investigators, designed the study and the sponsor conducted all the statistical analyses. The members of the steering committee were involved in the study design, reviewed the protocol, and provided guidance on the study conduct. All the authors had access to the data and contributed to data interpretation. All authors participated in the preparation of the manuscript with support from a professional medical writer, funded by Astellas Pharma Europe Ltd. All authors reviewed and approved the final version, and made the decision to submit the manuscript for publication and vouch for the completeness and accuracy of the data and analyses.</p><p><bold><italic>Financial support.</italic></bold>&#x02003;The TENPIN study was funded by Astellas Pharma Europe Ltd, Chertsey, United Kingdom.</p><p><bold><italic>Potential conflicts of interest.</italic></bold>&#x02003;F. S. has received speaker fees and/or research funding from, and/or has participated at advisory boards for, Novartis, Astellas, Roche, Genzyme, Merck Sharp &#x00026; Dohme, Gilead, Gambro, and Vital Therapies. A. P. has received research funding and speaker fees from Astellas, Novartis, Roche, Nycomed, TEVA, Genzyme, and has participated at advisory boards for Novartis. C. C. has received research grants, travel support, and/or lecture fees from Pfizer, Gilead, Merck, Astellas, Novartis, and Genzyme and has participated at advisory boards for Novartis and Genzyme. M. L. has received research grants from Merck Sharp &#x00026; Dohme and Pfizer. B. G.-E. has received speaker fees from Pfizer and speaker fees and research grants from Astellas and Novartis. L. F. is a member of an advisory committee for Novartis and has received grant support from Novartis and Astellas and speaker fees from Gilead Sciences. S. P. is an independent contractor employed by Astellas Pharma. L. T., A. K., and M. B. are full-time employees of Astellas Pharma. All other authors report no potential conflicts.</p><p>All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.</p></ack><ref-list><title>References</title><ref id="CIU1128C1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vera</surname><given-names>A</given-names></name><name><surname>Contreras</surname><given-names>F</given-names></name><name><surname>Guevara</surname><given-names>F</given-names></name></person-group><article-title>Incidence and risk factors for infections after liver transplant: single-center experience at the University Hospital Fundacion Santa Fe de Bogota, Colombia</article-title><source>Transpl Infect Dis</source><year>2011</year><volume>13</volume><fpage>608</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">21794041</pub-id></element-citation></ref><ref id="CIU1128C2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raghuram</surname><given-names>A</given-names></name><name><surname>Restrepo</surname><given-names>A</given-names></name><name><surname>Safadjou</surname><given-names>S</given-names></name><etal/></person-group><article-title>Invasive fungal infections following liver transplantation: incidence, risk factors, survival, and impact of fluconazole-resistant <italic>Candida parapsilosis</italic> (2003&#x02013;2007)</article-title><source>Liver Transpl</source><year>2012</year><volume>18</volume><fpage>1100</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">22577087</pub-id></element-citation></ref><ref id="CIU1128C3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zicker</surname><given-names>M</given-names></name><name><surname>Colombo</surname><given-names>AL</given-names></name><name><surname>Ferraz-Neto</surname><given-names>BH</given-names></name><name><surname>Camargo</surname><given-names>LF</given-names></name></person-group><article-title>Epidemiology of fungal infections in liver transplant recipients: a six-year study of a large Brazilian liver transplantation centre</article-title><source>Mem Inst Oswaldo Cruz</source><year>2011</year><volume>106</volume><fpage>339</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">21655823</pub-id></element-citation></ref><ref id="CIU1128C4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>CH</given-names></name><name><surname>He</surname><given-names>XS</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Fungal infection in patients after liver transplantation in years 2003 to 2012</article-title><source>Ann Transplant</source><year>2012</year><volume>17</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">23274325</pub-id></element-citation></ref><ref id="CIU1128C5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>XJ</given-names></name><name><surname>Lu</surname><given-names>SC</given-names></name><name><surname>He</surname><given-names>L</given-names></name><etal/></person-group><article-title>Diagnosis and treatment of fungal infection after liver transplantation</article-title><source>Chin Med J (Engl)</source><year>2011</year><volume>124</volume><fpage>1015</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21542960</pub-id></element-citation></ref><ref id="CIU1128C6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pacholczyk</surname><given-names>M</given-names></name><name><surname>Lagiewska</surname><given-names>B</given-names></name><name><surname>Lisik</surname><given-names>W</given-names></name><name><surname>Wasiak</surname><given-names>D</given-names></name><name><surname>Chmura</surname><given-names>A</given-names></name></person-group><article-title>Invasive fungal infections following liver transplantation&#x02014;risk factors, incidence and outcome</article-title><source>Ann Transplant</source><year>2011</year><volume>16</volume><fpage>14</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">21959504</pub-id></element-citation></ref><ref id="CIU1128C7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Fungal infections in the recipients of solid organ transplantation</article-title><source>Infect Dis Clin North Am</source><year>2003</year><volume>17</volume><fpage>113</fpage><lpage>34</lpage><comment>viii</comment><pub-id pub-id-type="pmid">12751263</pub-id></element-citation></ref><ref id="CIU1128C8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grossi</surname><given-names>PA</given-names></name></person-group><article-title>Clinical aspects of invasive candidiasis in solid organ transplant recipients</article-title><source>Drugs</source><year>2009</year><volume>69</volume><issue>suppl 1</issue><fpage>15</fpage><lpage>20</lpage><pub-id pub-id-type="pmid">19877729</pub-id></element-citation></ref><ref id="CIU1128C9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschenauer</surname><given-names>GA</given-names></name><name><surname>Lam</surname><given-names>SW</given-names></name><name><surname>Carver</surname><given-names>PL</given-names></name></person-group><article-title>Antifungal prophylaxis in liver transplant recipients</article-title><source>Liver Transpl</source><year>2009</year><volume>15</volume><fpage>842</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">19642130</pub-id></element-citation></ref><ref id="CIU1128C10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>PG</given-names></name><name><surname>Alexander</surname><given-names>BD</given-names></name><name><surname>Andes</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET)</article-title><source>Clin Infect Dis</source><year>2010</year><volume>50</volume><fpage>1101</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">20218876</pub-id></element-citation></ref><ref id="CIU1128C11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neofytos</surname><given-names>D</given-names></name><name><surname>Fishman</surname><given-names>JA</given-names></name><name><surname>Horn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Epidemiology and outcome of invasive fungal infections in solid organ transplant recipients</article-title><source>Transpl Infect Dis</source><year>2010</year><volume>12</volume><fpage>220</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20113459</pub-id></element-citation></ref><ref id="CIU1128C12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saliba</surname><given-names>F</given-names></name><name><surname>Delvart</surname><given-names>V</given-names></name><name><surname>Ichai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Fungal infections after liver transplantation: outcomes and risk factors revisited in the MELD era</article-title><source>Clin Transplant</source><year>2013</year><volume>27</volume><fpage>E454</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">23656358</pub-id></element-citation></ref><ref id="CIU1128C13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lichtenstern</surname><given-names>C</given-names></name><name><surname>Hochreiter</surname><given-names>M</given-names></name><name><surname>Zehnter</surname><given-names>VD</given-names></name><etal/></person-group><article-title>Pretransplant model for end stage liver disease score predicts posttransplant incidence of fungal infections after liver transplantation</article-title><source>Mycoses</source><year>2013</year><volume>56</volume><fpage>350</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">23346877</pub-id></element-citation></ref><ref id="CIU1128C14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Paterson</surname><given-names>DL</given-names></name></person-group><article-title><italic>Aspergillus</italic> infections in transplant recipients</article-title><source>Clin Microbiol Rev</source><year>2005</year><volume>18</volume><fpage>44</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">15653818</pub-id></element-citation></ref><ref id="CIU1128C15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Husain</surname><given-names>S</given-names></name></person-group><collab>the AST Infectious Diseases Community of Practice</collab><article-title>Invasive aspergillosis in solid organ transplant recipients</article-title><source>Am J Transplant</source><year>2009</year><volume>9</volume><issue>suppl 4</issue><fpage>S180</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">20070679</pub-id></element-citation></ref><ref id="CIU1128C16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>PG</given-names></name><name><surname>Kauffman</surname><given-names>CA</given-names></name><name><surname>Andes</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America</article-title><source>Clin Infect Dis</source><year>2009</year><volume>48</volume><fpage>503</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">19191635</pub-id></element-citation></ref><ref id="CIU1128C17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pappas</surname><given-names>PG</given-names></name><name><surname>Silveirab</surname><given-names>FP</given-names></name></person-group><collab>the AST Infectious Diseases Community of Practice</collab><article-title><italic>Candida</italic> in solid organ transplant recipients</article-title><source>Am J Transplant</source><year>2009</year><volume>9</volume><issue>suppl 4</issue><fpage>S173</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">20070678</pub-id></element-citation></ref><ref id="CIU1128C18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arendrup</surname><given-names>MC</given-names></name></person-group><article-title>Epidemiology of invasive candidiasis</article-title><source>Curr Opin Crit Care</source><year>2010</year><volume>16</volume><fpage>445</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">20711075</pub-id></element-citation></ref><ref id="CIU1128C19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krcmery</surname><given-names>V</given-names></name><name><surname>Barnes</surname><given-names>AJ</given-names></name></person-group><article-title>Non-albicans <italic>Candida</italic> spp. causing fungaemia: pathogenicity and antifungal resistance</article-title><source>J Hosp Infect</source><year>2002</year><volume>50</volume><fpage>243</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">12014897</pub-id></element-citation></ref><ref id="CIU1128C20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deray</surname><given-names>G</given-names></name></person-group><article-title>Amphotericin B nephrotoxicity</article-title><source>J Antimicrob Chemother</source><year>2002</year><volume>49</volume><issue>suppl 1</issue><fpage>37</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">11801579</pub-id></element-citation></ref><ref id="CIU1128C21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>HY</given-names></name><name><surname>Cacciarelli</surname><given-names>TV</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name></person-group><article-title>Micafungin versus amphotericin B lipid complex for the prevention of invasive fungal infections in high-risk liver transplant recipients</article-title><source>Transplantation</source><year>2013</year><volume>96</volume><fpage>573</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">23842191</pub-id></element-citation></ref><ref id="CIU1128C22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Glockner</surname><given-names>A</given-names></name></person-group><article-title>Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin: review of the literature</article-title><source>Eur J Med Res</source><year>2011</year><volume>16</volume><fpage>167</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">21486731</pub-id></element-citation></ref><ref id="CIU1128C23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Wagener</surname><given-names>MM</given-names></name><name><surname>Cacciarelli</surname><given-names>TV</given-names></name><name><surname>Levitsky</surname><given-names>J</given-names></name></person-group><article-title>Antifungal management practices in liver transplant recipients</article-title><source>Am J Transplant</source><year>2008</year><volume>8</volume><fpage>426</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">18190655</pub-id></element-citation></ref><ref id="CIU1128C24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cornely</surname><given-names>OA</given-names></name><name><surname>Bassetti</surname><given-names>M</given-names></name><name><surname>Calandra</surname><given-names>T</given-names></name><etal/></person-group><article-title>ESCMID guideline for the diagnosis and management of <italic>Candida</italic> diseases 2012: non-neutropenic adult patients</article-title><source>Clin Microbiol Infect</source><year>2012</year><volume>18</volume><issue>suppl 7</issue><fpage>19</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">23137135</pub-id></element-citation></ref><ref id="CIU1128C25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gavalda</surname><given-names>J</given-names></name><name><surname>Meije</surname><given-names>Y</given-names></name><name><surname>Fortun</surname><given-names>J</given-names></name><etal/></person-group><article-title>Invasive fungal infections in SOT recipients</article-title><source>Clin Microbiol Infect</source><year>2014</year><volume>20</volume><issue>suppl 7</issue><fpage>27</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">24810152</pub-id></element-citation></ref><ref id="CIU1128C26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Pauw</surname><given-names>B</given-names></name><name><surname>Walsh</surname><given-names>TJ</given-names></name><name><surname>Donnelly</surname><given-names>JP</given-names></name><etal/></person-group><article-title>Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group</article-title><source>Clin Infect Dis</source><year>2008</year><volume>46</volume><fpage>1813</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18462102</pub-id></element-citation></ref><ref id="CIU1128C27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Moher</surname><given-names>D</given-names></name></person-group><article-title>CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials</article-title><source>Ann Intern Med</source><year>2010</year><volume>152</volume><fpage>726</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">20335313</pub-id></element-citation></ref><ref id="CIU1128C28"><label>28</label><element-citation publication-type="other"><collab>Astellas Pharma Europe B.V</collab><article-title>Mycamine: summary of product characteristics</article-title><comment>Available at: <uri xlink:type="simple" xlink:href="https://www.medicines.org.uk/emc/medicine/20997/SPC/Mycamine+50mg+and+100mg+powder+for+solution+for+infusion/">https://www.medicines.org.uk/emc/medicine/20997/SPC/Mycamine+50mg+and+100mg+powder+for+solution+for+infusion/</uri>. Accessed 26 February 2014</comment></element-citation></ref><ref id="CIU1128C29"><label>29</label><element-citation publication-type="other"><collab>Astellas Pharma US Inc</collab><article-title>Mycamine prescribing information</article-title><comment>Available at: <uri xlink:type="simple" xlink:href="https://www.mycamine.com/PrescribingInformation.aspx">https://www.mycamine.com/PrescribingInformation.aspx</uri>. Accessed 26 February 2014.</comment></element-citation></ref><ref id="CIU1128C30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Burik</surname><given-names>JA</given-names></name><name><surname>Ratanatharathorn</surname><given-names>V</given-names></name><name><surname>Stepan</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation</article-title><source>Clin Infect Dis</source><year>2004</year><volume>39</volume><fpage>1407</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">15546073</pub-id></element-citation></ref><ref id="CIU1128C31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfaller</surname><given-names>MA</given-names></name><name><surname>Diekema</surname><given-names>DJ</given-names></name></person-group><article-title>Epidemiology of invasive candidiasis: a persistent public health problem</article-title><source>Clin Microbiol Rev</source><year>2007</year><volume>20</volume><fpage>133</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">17223626</pub-id></element-citation></ref><ref id="CIU1128C32"><label>32</label><element-citation publication-type="other"><collab>Pfizer Ltd</collab><article-title>Diflucan: summary of product characteristics</article-title><comment>Available at: <uri xlink:type="simple" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diflucan_30/WC500121908.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diflucan_30/WC500121908.pdf</uri>. Accessed 26 February 2014</comment></element-citation></ref><ref id="CIU1128C33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pittrow</surname><given-names>L</given-names></name><name><surname>Penk</surname><given-names>A</given-names></name></person-group><article-title>Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD)</article-title><source>Mycoses</source><year>1999</year><volume>42</volume><fpage>17</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">10394842</pub-id></element-citation></ref><ref id="CIU1128C34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muhl</surname><given-names>E</given-names></name><name><surname>Martens</surname><given-names>T</given-names></name><name><surname>Iven</surname><given-names>H</given-names></name><name><surname>Rob</surname><given-names>P</given-names></name><name><surname>Bruch</surname><given-names>HP</given-names></name></person-group><article-title>Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole</article-title><source>Eur J Clin Pharmacol</source><year>2000</year><volume>56</volume><fpage>671</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11214774</pub-id></element-citation></ref><ref id="CIU1128C35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moen</surname><given-names>MD</given-names></name><name><surname>Lyseng-Williamson</surname><given-names>KA</given-names></name><name><surname>Scott</surname><given-names>LJ</given-names></name></person-group><article-title>Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections</article-title><source>Drugs</source><year>2009</year><volume>69</volume><fpage>361</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">19275278</pub-id></element-citation></ref><ref id="CIU1128C36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eschenauer</surname><given-names>GA</given-names></name><name><surname>DePestel</surname><given-names>DD</given-names></name><name><surname>Carver</surname><given-names>PL</given-names></name></person-group><article-title>Comparison of echinocandin antifungals</article-title><source>Ther Clin Risk Manag</source><year>2007</year><volume>3</volume><fpage>71</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">18360617</pub-id></element-citation></ref><ref id="CIU1128C37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SC</given-names></name><name><surname>Slavin</surname><given-names>MA</given-names></name><name><surname>Sorrell</surname><given-names>TC</given-names></name></person-group><article-title>Echinocandin antifungal drugs in fungal infections: a comparison</article-title><source>Drugs</source><year>2011</year><volume>71</volume><fpage>11</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">21175238</pub-id></element-citation></ref><ref id="CIU1128C38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beyda</surname><given-names>ND</given-names></name><name><surname>Lewis</surname><given-names>RE</given-names></name><name><surname>Garey</surname><given-names>KW</given-names></name></person-group><article-title>Echinocandin resistance in <italic>Candida</italic> species: mechanisms of reduced susceptibility and therapeutic approaches</article-title><source>Ann Pharmacother</source><year>2012</year><volume>46</volume><fpage>1086</fpage><lpage>96</lpage><pub-id pub-id-type="pmid">22811350</pub-id></element-citation></ref><ref id="CIU1128C39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlin</surname><given-names>DS</given-names></name></person-group><article-title>Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management</article-title><source>Drugs</source><year>2014</year><volume>74</volume><fpage>1573</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">25255923</pub-id></element-citation></ref><ref id="CIU1128C40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexander</surname><given-names>BD</given-names></name><name><surname>Johnson</surname><given-names>MD</given-names></name><name><surname>Pfeiffer</surname><given-names>CD</given-names></name><etal/></person-group><article-title>Increasing echinocandin resistance in <italic>Candida glabrata</italic>: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations</article-title><source>Clin Infect Dis</source><year>2013</year><volume>56</volume><fpage>1724</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">23487382</pub-id></element-citation></ref><ref id="CIU1128C41"><label>41</label><element-citation publication-type="other"><collab>Merck Sharp &#x00026; Dohme Ltd</collab><article-title>Cancidas: summary of product characteristics</article-title><comment>Available at: <uri xlink:type="simple" xlink:href="http://www.medicines.org.uk/emc/medicine/12843#PHARMACOKINETIC_PROPS">http://www.medicines.org.uk/emc/medicine/12843#PHARMACOKINETIC_PROPS</uri> Accessed 26 February 2014</comment></element-citation></ref><ref id="CIU1128C42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>MF</given-names></name><name><surname>Townsend</surname><given-names>RW</given-names></name><name><surname>Austin</surname><given-names>S</given-names></name><etal/></person-group><article-title>Concomitant cyclosporine and micafungin pharmacokinetics in healthy volunteers</article-title><source>J Clin Pharmacol</source><year>2005</year><volume>45</volume><fpage>954</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">16027407</pub-id></element-citation></ref><ref id="CIU1128C43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Drug interactions between micafungin at high doses and cyclosporine A in febrile neutropenia patients after allogeneic hematopoietic stem cell transplantation</article-title><source>Int J Clin Pharmacol Ther</source><year>2012</year><volume>50</volume><fpage>831</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">22943928</pub-id></element-citation></ref><ref id="CIU1128C44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hebert</surname><given-names>MF</given-names></name><name><surname>Blough</surname><given-names>DK</given-names></name><name><surname>Townsend</surname><given-names>RW</given-names></name><etal/></person-group><article-title>Concomitant tacrolimus and micafungin pharmacokinetics in healthy volunteers</article-title><source>J Clin Pharmacol</source><year>2005</year><volume>45</volume><fpage>1018</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">16100295</pub-id></element-citation></ref><ref id="CIU1128C45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuoka</surname><given-names>N</given-names></name><name><surname>Imataki</surname><given-names>O</given-names></name><name><surname>Ohnishi</surname><given-names>H</given-names></name><etal/></person-group><article-title>Micafungin does not influence the concentration of tacrolimus in patients after allogeneic hematopoietic stem cell transplantation</article-title><source>Transplant Proc</source><year>2010</year><volume>42</volume><fpage>2725</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">20832577</pub-id></element-citation></ref></ref-list><app-group><app><title>APPENDIX</title><p><bold><italic>Independent Data Review Board.</italic></bold> Dr Claudio Viscoli, University of Genoa, Genoa, Italy; Dr Jean-Pierre Gangneux, H&#x000f4;pital Pontchaillou, Rennes, France; Professor Manuel Cuenca-Estrella, Instituto de Salud Carlos III, Madrid, Spain.</p><p><bold><italic>TENPIN Study Investigators.</italic></bold> Johann Pratschke, Universit&#x000e4;tsklinik Innsbruck, Austria; Johan Decruyenaere and Jan J. De Waele, Ghent University Hospital, Belgium; Pierre-Fran&#x000e7;ois Laterre, St Luc University Hospital, Universit&#x000e9; catholique de Louvain, Belgium; Christophe Moreno, H&#x000f4;pital Universitaire Erasme, Belgium; Peter Michielsen, Universitair Ziekenhuis, Belgium; Olivier Cointault, H&#x000f4;pital de Rangueil, France; Lutz Fischer, University Medical Center Hamburg-Eppendorf, Germany; Peter Neuhaus and Andreas Pascher, Charit&#x000e9; Universit&#x000e4;tsmedizin, Germany; Peter Schemmer, Universit&#x000e4;tsklinikum Heidelberg, Germany; Carlos Cervera, Hospital Clinic i Provincial, Spain; Evaristo Varo, Hospital Cl&#x000ed;nico Universitario de Santiago, Spain; Miguel Montejo, Hospital de Cruces, Spain; Emilio Bouza, Hospital Universitario Gregorio Maranon, Spain; Marino Blanes, Hospital Universitari I Politecnic La Fe de Valencia, Spain; Juan Carlos Pozo, Hospital Universitario Reina Sofia, Spain; Jesus Fortun, Hospital Ramon y Cajal, Spain; Faouzi Saliba, H&#x000f4;pital Paul Brousse, France; Lionel Rostaing, Hopital de Rangueil, France; Catherine Paugam-Burtz, H&#x000f4;pital Beaujon, France; Daniel Eyraud, Hopital Pitie-Salpetriere, France; Tahir Shah, Queen Elizabeth Hospital, United Kingdom; Nigel Heaton, Kings College Hospital, United Kingdom; R&#x000f3;bert M. Langer, Semmelweis University, Hungary; Aiden McCormick, St Vincent's University Hospital, Ireland; Umberto Cillo, Azienda Ospedaliera-Universit&#x000e0; di Padova, Italy; Mauro Salizzoni, Azienda Ospedaliero Univ S. Giovanni Battista di Torino, Italy; Manuela Lugano, Azienda Ospedaliero-Universitaria di Udine, Italy; Andrea De Gasperi, Azienda Ospedaliera Ospedale Niguarda Ca&#x02019; Granda, Italy; Lu&#x000ed;s Tom&#x000e9;, Hospitais Universidade Coimbra, Portugal; Jorge Daniel, Hospital Geral de Santo Antonio, Portugal; Irinel Popescu, Fundeni Clinical Institute, Romania; Yan G. Moysyuk, Sc. Research Institute of Transplantology and Artificial Organs, Russian Federation; Alexey V. Chzhao, Sc. Research Institute of Emergency Care, Russian Federation; Vladimir E. Zagaynov, Privolzhsky District Medical Centre, Russian Federation; Bo-G&#x000f6;ran Ericzon, Karolinska University Hospital, Sweden.</p></app></app-group></back></article>